货号（Catalog No.）icon

CSD00089

通用名INNicon

Rituximab

纯度(Purity)icon

>95%

电泳图（SDS-PAGE image）icon

浓度( Concentration)icon

1mg/ml

Formulationicon

PBS buffer pH7.5

Sourceicon

CHO cells

内毒素(Endotoxin level)icon

Please contact with the lab for this information.

生物活性icon

产品描述(Description)

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan (Rituximab) 7.Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label.

别名(Alternative names)

IDEC-C2B8

靶点;物种(Specificity target name;species)

MS4A1[Homo sapiens]

活性研究（体外/体内研究）(Activity in vitro)

Complement-dependent cytotoxicity(CDC), complement-dependent cellular cytotoxicity(CDCC), antibody-dependent cytotoxicity (ADCC) as well as the induction of apoptosis have been claimed to be responsible for the efficacy of rituximab. Rituximab can induce death of malignant B cell lines in vitro. The strength of this effect varies considerably between target cell lines. Changes that have been identified in response to rituximab in vitro include inhibition of p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways. Rituximab is highly efficient at mediating CMC(complement dependent cytotoxicity) of various B cell lines as well as fresh malignant B cell samples. CD20-binding capacity of rituximab is dose-dependent.

种类(Species)

Chimeric

受体鉴定(Receptor identification)

IgG1-kappa

化学信息icon

分子量(MV)

148000.00 Da

CAS

174722-31-7

存储条件(Storage)

store at -80°C

Note
For research use only .